Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate
Journal of the Peripheral Nervous System · 2026-06 · 31 (2)
DOI: 10.1111/jns.70124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of the Peripheral Nervous System, online erschienen am 17.05.2026. Verfasst von Gordon Sloan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Medicine, University of Sheffield, Sheffield, UK. Hauptthemen laut MEDLINE: Diabetic Neuropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.
Abstract (Originalsprache)
Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, yet whether established clinical DPN is reversible remains debated. At the 35th Annual Meeting of NEUROdiab, a formal debate examined arguments ‘for’ and ‘against’ the proposition that clinical DPN can be reversed. This review summarises both perspectives and considers their implications for clinical practice and future research. Evidence supporting the reversibility of clinical DPN draws on four main observations. Therapies for hereditary transthyretin amyloidosis demonstrate that substantial improvement in a progressive length‐dependent neuropathy is biologically achievable, providing a proof‐of‐concept in a different disease. Pancreatic transplantation in Type 1 diabetes leads to measurable improvements in large‐ and small‐fibre indices. Structured lifestyle interventions and bariatric surgery improve intraepidermal nerve fibre density, suggesting that metabolic correction can promote neural repair. Finally, emerging agents such as topical oxybutynin show early promise in improving surrogate outcomes, reinforcing the argument that clinical DPN may be partially reversible. Arguments opposing reversibility emphasise that DPN resembles other microvascular complications, in which early abnormalities may regress but established clinical disease is not reversed. Heterogeneity in diagnostic thresholds, phenotype variability and inconsistent outcome measures complicates defining what constitutes true reversal. Long‐term studies and major trials, including DCCT/EDIC and BARI 2D, demonstrate slowing of progression rather than restoration of normal nerve function. Moreover, numerous mechanistically promising agents have failed in human trials despite strong pre‐clinical results. Collectively, these limitations support the view that established clinical neuropathy remains largely irreversible to date. Overall, the debate underscores that reversibility depends on timing, definitions and outcome thresholds. While early‐stage dysfunction is more likely to be modifiable, complete restoration of established clinical DPN (such as full restoration of protective sensation) remains unproven. Future research should prioritise developing validated biomarkers and standardised endpoints in addition to searching for new therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Clinical Medicine, University of Sheffield, Sheffield, UK.
- Centre for Diabetes, Endocrinology and Metabolism, Manchester University NHS Foundation Trust, Manchester, UK.
- Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
- Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA.
- Department of Anatomy, Cell Biology, and Physiological Sciences, Faculty of Medicine and Medical Center, American University of Beirut, Beirut, Lebanon.
- Manchester University NHS Foundation Trust, Manchester, UK.
ORCID-Profile: Gordon Sloan, Shazli Azmi, Stephanie Eid, Maryam Ferdousi, Johan Røikjer, Zoltan Kender, Luca D'Onofrio, Eleni Karlafti, Brian Callaghan, Bruce A Perkins
Förderung
- NIDDK NIH HHS
Zitieren
APA
Sloan, G., Azmi, S., Eid, S., Ferdousi, M., Røikjer, J., Kender, Z., D'Onofrio, L., Karlafti, E., Callaghan, B., & Perkins, B. A. (2026). Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate. Journal of the Peripheral Nervous System, 31(2). https://doi.org/10.1111/jns.70124
Vancouver
Sloan G, Azmi S, Eid S, Ferdousi M, Røikjer J, Kender Z, et al. Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate. Journal of the Peripheral Nervous System. 2026;31(2). doi:10.1111/jns.70124
BibTeX
@article{Sloan2026,
author = {Sloan, Gordon and Azmi, Shazli and Eid, Stephanie and Ferdousi, Maryam and Røikjer, Johan and Kender, Zoltan and D'Onofrio, Luca and Karlafti, Eleni and Callaghan, Brian and Perkins, Bruce A},
title = {Clinical Diabetic Peripheral Neuropathy: Can It Be Reversed? Arguments for and Against From a NEUROdiab Debate},
journal = {Journal of the Peripheral Nervous System},
year = {2026},
volume = {31},
number = {2},
doi = {10.1111/jns.70124}
}
EUVIMED